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Abstract
Background: Glomerular diseases are potentially fatal, requiring aggressive interventions and close monitoring.
Urine is a readily-accessible body fluid enriched in molecular signatures from the kidney and therefore particularly
suited for routine clinical analysis as well as development of non-invasive biomarkers for glomerular diseases.
Methods: The Nephrotic Syndrome Study Network (NEPTUNE; ClinicalTrials.gov Identifier NCT01209000) is a North
American multicenter collaborative consortium established to develop a translational research infrastructure for
nephrotic syndrome. This includes standardized urine collections across all participating centers for the purpose of
discovering non-invasive biomarkers for patients with nephrotic syndrome due to minimal change disease, focal
segmental glomerulosclerosis, and membranous nephropathy. Here we describe the organization and methods of
urine procurement and banking procedures in NEPTUNE.
Results: We discuss the rationale for urine collection and storage conditions, and demonstrate the performance of
three experimental analytes (neutrophil gelatinase-associated lipocalin [NGAL], retinol binding globulin, and alpha-1
microglobulin) under these conditions with and without urine preservatives (thymol, toluene, and boric acid). We
also demonstrate the quality of RNA and protein collected from the urine cellular pellet and exosomes.
Conclusions: The urine collection protocol in NEPTUNE allows robust detection of a wide range of proteins and
RNAs from urine supernatant and pellets collected longitudinally from each patient over 5 years. Combined with
the detailed clinical and histopathologic data, this provides a unique resource for exploration and validation of new
or accepted markers of glomerular diseases.
Trial registration: ClinicalTrials.gov Identifier NCT01209000
Keywords: Exosome, Urinalysis, Urine specimen collection
Background
There is currently considerable interest in developing
urine procurement protocols for longitudinal clinical
studies that collect and process large numbers of sam-
ples from patients with kidney disease, and specifically
with various glomerular diseases. Utilizing these samples
for diverse research questions in both basic and clinical
studies of glomerular disease could help to advance the
understanding of glomerular disease pathogenesis [1].
However, few, if any, published reports discuss the ra-
tionale or strategy for serial urine collections and opti-
mal storage conditions [2–6]. Those published studies
that do so focus on subcomponents of urine, and exam-
ine only limited numbers of abundant analytes. Further-
more, little rationale or strategy exists in these prior
studies to inform the protocols needed for multicenter
clinical studies [2].
NEPTUNE (Clinical trials.gov: NCT01209000) is a
multicenter study that is identifying and prospectively
following 450 incident, biopsy-proven cases of nephrotic
syndrome (NS) from membranous nephropathy (MN),
minimal change disease (MCD), or focal segmental
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glomerulosclerosis (FSGS) (or other glomerulopathies
groups/OG if none of the above). Currently, 21 academic
clinical centers in the United States and Canada are par-
ticipating in the NEPTUNE protocol [7] designed for
systems biology approaches to phenotype-genotype cor-
relations. As part of the NEPTUNE protocol, urine
samples are being collected at 11 time points over
30 months for clinical outcome measures (total protein,
albumin excretion), as well as to establish a urine Bio-
bank for further ancillary studies on these rare diseases.
Urine is a logical place to identify potential biomarkers
of kidney disease. Urinary neutrophil gelatinase-associated
lipocalin (NGAL, LCN2) is up-regulated after tubular cell
injury and may also be a marker of kidney disease and se-
verity in chronic kidney disease, including FSGS [8, 9].
Levels of NGAL may differentiate the steroid sensitive
from the steroid resistant form and correlate with disease
severity in steroid resistant nephrotic syndrome [10].
Alpha-1 microglobulin (AMBP; AMBP) and retinol bind-
ing protein (RBP) are low molecular weight markers of
proximal tubular dysfunction [11–13]. Alpha-1 microglob-
ulin has been proposed to correlate with the extent of
tubulointerstitial damage in membranous nephropathy
and to have a predictive value for functional outcome and
response to therapy that is superior to 24-h proteinuria
[14]. Urinary RBP is also a marker of tubulointerstitial dis-
ease [12, 15]. Podocalyxin (PODXL), fibrocystin (FIBRO),
polycystin 1 (PC1) and smoothened (SMO) are implicated
in the glomerular or tubular disorders and present in
urine or its exosome subfraction in low abundance but de-
tectable with well-validated antibody reagents that were
available to us at the time these studies were performed
[16–22]. RNA obtained from urine cellular pellets, micro-
vesicles, and urine metabolites are now showing promise
for identification of disease biomarkers [23–25].
Here, we discuss some of the challenges in implement-
ing a urine collection protocol across multiple clinical
sites. We present results that define storage and preser-
vation conditions that would allow for analyses of urine
proteins (especially proteomic studies), RNA, and DNA,
from both soluble urine fractions and exosomes, as
sources of biomarkers of interest to the nephrology
community [6, 26, 27].
Methods
Urine stability studies
Stability studies were performed on waste urine ob-
tained from the Mayo Renal Function Laboratory.
Urines (25–50 mL) were retrieved within 2 h of collec-
tion from patients with and without proteinuria with-
out preservative (random samples). Contaminated
samples, assessed as a positive Gram’s stain, were not
used. Samples were studied over 1–7 days under the
following preservative conditions: 1) ambient (room
temperature [RT] without preservative), 4 °C, and −20 °C
without preservative; 2) ambient (RT) with addition of
toluene, thymol, acetic acid, boric acid, 6 N HCl 50 %
acetic acid; 3) addition of Roche Complete (no EDTA) and
Sigma protease inhibitors and samples either immediately
then frozen at −80 °C or exosomes extracted and stored in
100 μL of 0.25 M Sucrose 20 mM HEPES (pH 7.4) with
added Complete at −80 °C. Up to 10 independent urine
samples were assessed for each biomarker studied. Bio-
markers were measured at time zero, 1, 3 and 7 days after
urine collection. Biomarkers were considered stable if
mean values were within 20 % of time zero measurements.
The Mayo Clinic Institutional Review Board approved
studies using waste urines; therefore, informed consent
was waived (IRB # 09–004285). All NEPTUNE (Clinical
trials.gov: NCT01209000; date of entry July 29, 2010) local
sites obtained IRB approval and patients provided in-
formed consent or parental assent for urine collections;
located at University of Michigan Medical Center, New
York University Langone Medical Center, Johns Hopkins
Medical Institute, John H. Stroger Cook County Hospital,
University Health Network – Toronto, University Hospi-
tals Case Medical Center, University of Southern
California Lost Angeles Children’s Hospital, Los Angeles
Biomedical Research Institute, Steven and Alexandra
Cohen Children’s Medical Center of New York, The Mayo
Clinic, Children’s Hospital at Montefiore Medical Center,
University of Miami - Miller School of Medicine, Univer-
sity of North Carolina at Chapel Hill, Children’s Hospital
of Philadelphia, Seattle Children’s Hospital, Providence
Medical Center, NIDDK, Columbia University, Temple
University, Emory University - Children’s Hospital of
Atlanta, Stanford University, University of Texas at
Southwestern.
Candidate biomarkers
Soluble proteins
NGAL was measured using a Bioporto Rapid ELISA
[28]. AMBP and RBP were measured on a Siemens BN
II nephelometer using kits from Siemens and The Bind-
ing Site, respectively.
Cellular pellet proteins
PODXL, FIBRO, and SMO were examined in urine pel-
lets across several storage conditions with and without
preservatives collected using the NEPTUNE protocol
(Fig. 1, Additional Methods-Manuals of Procedures for
Spot Urine and for 24-h Urine Processing).
Cellular pellet DNA
To examine DNA quality from cellular pellets, the large
PKD1 gene in a region of the genome that is highly repeti-
tive was examined using the robust Multiplex Ligation-
dependent Probe Amplification (MLPA) method which is
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a multiplex PCR method detecting abnormal copy num-
bers of genomic DNA; commercial kits are available for
up to 50 genes. In this commercially-available kit, oligo-
nucleotide probes are designed to make the ligated base
overlie the site of sequence differences among highly simi-
lar sequences allowing discrimination of unique sequence
copy numbers, hence giving us a way to determine DNA
quality across the genomic region of PKD1 for the first
time in urine cellular pellets and permitting study of som-
atic mutations in candidate genes in the NEPTUNE
cohort.
Cellular pellet RNA
To examine urine RNA expression, the frozen urine pel-
let was thawed on ice, and either RNA was isolated dir-
ectly, or pellet was washed by suspending it in 1.5 mL
DEPC-treated PBS, transferred to a 1.6 mL Eppendorf
tube, and then centrifuged at 13,000 g for 5 min at 4 °C.
We examined pellet RNA isolated from urine cellular
pellets, and RNA was isolated using the column-based
method (i.e., RNeasy, Qiagen) at Mayo Clinic; the NEP-
TUNE pellets were studied in Michigan. For detection
of mRNAs, qRT-PCR was performed for podocin,
nephrin, aquaporin2, and TGF-β1 as described [23].
MicroRNAs were detected using TaqMan® microRNA
arrays (Applied Biosystems) as described [29].
Results
NEPTUNE urine collection protocol
A defined urine collection procedure (Table 1; Additional
file 1: Table S1; and Additional Methods-Manuals of Pro-
cedures for Spot Urine and for 24-h Urine Processing)
was created based upon best practices and literature re-
view [30, 31]. This approach was employed to provide a
standardized collection procedure applied to all participat-
ing centers. Samples are collected using two working pro-
tocols: (1) from 24-h whole urine collection, and (2) spot
urine collections (recorded as “am” or “pm” void). A total
of 13 visits are planned for the anticipated 600 participants
in the study. In each visit, a total of 11 tubes will be gener-
ated: three 5 mL tubes (n = 4 times), seven 2 mL tubes (n
= 12), and one 50 mL tube (n = 2). In other words, a total
of 121 samples will be generated per participant over 13
visits. To date, about 400 participants have been enrolled
in the study. We anticipate there will be up to 72,600
urine samples collected through the study timeframe.
Study dependent urine based outcomes
To determine the rates of two clinical outcomes, change
in urinary protein excretion and change in kidney func-
tion will be determined in both major disease groups
(MCD/FSGS and MN that are fully histopathologically
characterized; Additional file 1: Table S2). The urine
(See figure on previous page.)
Fig. 1 a NEPTUNE spot urine sample processing: Sample 1: 4 × 2 mL cryovials whole unprocessed “raw” urine (SU). Sample 2: 4 × 2 mL samples
with sodium azide additive (AS). Supernatant after low speed centrifugation is saved in cryovials with 20 μL 100 mM sodium azide (12 mL × 4).
Sodium azide has anti-bacterial properties. Sample 3: 4 cryovials with proteinase inhibitor (PI). Sample 4: 2 sets of pellet from this are stored in
RNAlater obtained by centrifugation at 1000 g × 12 min in a tabletop centrifuge (AP-E). Sample 5: 4 × 2 mL from the PI sample. 2 sets of pellet
from this are stored in in RNAlater obtained by centrifugation at 1000 g x 12 min in a tabletop centrifuge (AQ-Q). All samples are stored on ice in
transport and during collection. All samples are frozen as soon possible at −80 °C. Cryovial final volume stored is 1.6 mL urine. b NEPTUNE 24-h
urine sample processing. One subaliquot 40 mL whole urine (inverted x 3) frozen at −80 °C immediately (U1). 1 subaliquot (40 mL) of whole urine
with protease inhibitor (6 μL; Sigma P1860) (UQ1); 5 × 5 mL cryovials whole urine (U-24)
Table 1 NEPTUNE Urine Collection Timeline
Visit Numbera V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13
Eligibility assessment X
Baseline H&P X
Follow-up H&P X X X X X X X X X X
Biosample baseline X
Biosample follow-up X X X X X X X X X X
24-hour urine X X X X X X X X
Clean catch/(Spot) urine X X X X X X X X X X X
Renal biopsy tissue Xb
Abbreviations: H&P history and physical examination, UA urinalysis, macroscopic (color, appearance, specific gravity, pH, leukocyte esterase, nitrite, protein,
glucose, ketones, urobilin, bilirubin, blood), V visit
aThere will be a total of 13 visits for the anticipated 600 participants in the study. In each visit, a total of 11 tubes will be generated (3 of 5 mL tubes, 7 of 2 mL
tubes and 1 of 50 mL tube)
bRenal biopsy includes a pre-biopsy 10 mL spot urine
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protein measures will be performed at a single Central
Reference Laboratory (Mayo Clinic, Rochester, Minne-
sota). A 24-h urine protein quantitation will be performed
at each clinical site per this protocol for real time clinical
care. The urine outcome will be performed on one of the
three 5 mL tubes for each collection. A spot and 24-h
urine albumin, creatinine (gold standard) and total protein
will be measured by the Central Reference lab for the
study primary outcomes. Spot urines for protein/creatin-
ine ratio will also be obtained according to the study
protocol and compared with the values from the 24-h
urines. Each enrollee receives a unique patient identifier
(PID), which is applied to all components of their col-
lected urine samples (Additional file 1: Table S2). The
NEPTUNE study, including the urine collection protocol,
was approved by the Institutional Review Boards at all
participating institutions (currently at 21). The study was
conducted in adherence to the Declaration of Helsinki.
Written informed consent for participation in the study
was obtained from participants or, where participants are
children, a parent or guardian.
Local center collections
Clinical Research Units are used at each site for these
standardized biosample collections. All sites have re-
ceived standardized training. Special attention will be
given to facilitate the collection of urines in pediatric pa-
tients enrolled in this study. For incontinent infants and
children, urine may be collected using a urine collection
bag for a spot sample or a timed void.
Urine protein stability
Soluble protein biomarkers
All 3 proteins tested (NGAL, AMBP, RBP) were stable
for up to 7 days at RT, 4 °C, and −20 °C (Fig. 2a-c).
They were also stable with toluene, thymol, and boric
acid preservatives, but not with acetic acid, 6 N HCl,
or 6 N HNO3 (Additional file 2: Table S3). These 3
proteins were stable for up to 3 freeze/thaw cycles at
−20 °C. Therefore, urine samples stored frozen with-
out preservative will be adequate for selected urine
proteins [32]. Other biomarkers susceptible to urinary
proteases may require more specialized handling (see
below).
Cost analysis and protein stability studies with protease
inhibitors
To collect suitable samples for future detailed proteomics
studies, we evaluated two commercially-available protease
inhibitors: Sigma protease inhibitor P 1860 TM (Sigma-Al-
drich Corp., St. Louis, MO) and Roche Complete mini pro-
tease inhibitor (Complete, EDTA free, 11873580001, Roche
Diagnostics Corp, Indianapolis, IN) and examined several
proteins of interest by Western analysis (Additional file 1:
Figure S1). We found the Sigma protease cocktail was not
only more efficient in preserving the proteins of interest,
but that it was also significantly less expensive, as it could
be divided for use across the sub-aliquots being collected
for the future proteomics studies of this trial (Additional
file 1: Table S1). Indeed 20 % less Sigma protease inhibitor
was just as efficient as the recommended amounts by
the manufacturer in preserving the proteins that we
tested (Additional file 1: Figure S1). The protocol em-
ploys 6 μL per 50 mL urine contained (containing
40 mL urine = 4.8 μL/40 mL).
Cellular pellet proteins
We also examined protein stability in cellular pellets for
selected proteins using Western analysis, with and with-
out the above protease inhibitors (Additional file 1:
Figure S1). There was substantially better detection of
the podocyte marker of interest PODXL in cellular pel-
lets stored with protease inhibitors, and again found that
Sigma protease inhibitor product may in fact be superior
to the more expensive Roche protease inhibitor cocktail
(Additional file 1: Figure S1). Without the presence of
protease inhibitor, the proteins we examined (podoca-
lyxin, fibrocystin and smoothened) did not survive
12 months of storage (6 month representative Western
shown), or a freeze/thaw cycle at −80 °C. Fibrocystin
and smoothened were only variably preserved under any
conditions tested.
Exosomal proteins
To evaluate the impact of freezing on the integrity of
exosomes in stored urine, we compared exosome prepa-
rations after raw urine was stored at RT, 4 °C, or −80 °C
for 0, 1, 3, or 7 days. The urine exosome protein PC1
was readily detected from urine stored at RT and 4 °C
for up to 7 days, but there was a marked decrease in
detectable protein in the urine thawed after any period
of −80 °C storage. However, exosomal proteins in the
samples stored at RT and 4 °C were detectable out to
day seven (Fig. 3), which might permit shipping of such
samples from a clinical site to a research laboratory for
subsequent isolation of exosomes. The loss of the PC1
with storage at −80 °C is likely due to protein aggrega-
tion, which led to loss of the exosome fraction after
thawing, and a low-speed spin done to pre-clear the
urine sample in preparation for ultracentrifugation.
Several exosomal proteins were examined (PODXL,
FIBRO, and PC1) by Western blot in exosomes stored
with protease inhibitor in comparison to freshly isolated
exosomes. We found that PC1 is stable for 1 week after
isolation of exosomes when stored (in 0.01 % sodium
azide with protease inhibitor tablet [Roche]) were stable
at RT and 4 °C (Fig. 3a of representative data). FIBRO
was well preserved in exosomes stored with or without
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protease inhibitor, whereas it was not well detected in
cell pellets under these conditions, especially with
storage. Scramblase (PLSCR1) was well preserved with
Sigma protease inhibitor and one freeze/thaw cycle. As
with cellular pellets, in general, addition of protease
inhibitor was essential to protein survival (Fig. 3b-d,
Additional file 1: Figure S1).
Long-term (≤twelve month storage data) for exosomes
extracted from Raw urine
The exosomal proteins SMO, PODXL, FIBRO,
PLSCR1 and PC1 were detected in exosomes that were
isolated from fresh urine, then stored at −80 °C for
12 months, without any evidence that they degraded
(Fig. 3e).
DNA integrity from cellular pellets
The MLPA technique allows simultaneous screening of
multiple target sequences in a single reaction by using
pairs of probes that carry tails for binding of common
amplification primers. To test if this technique could be
applied to evaluate disease gene transcripts present in
urine pellets, we examined the large polycystic kidney
disease gene PKD1 transcript by MLPA and long-range
PCR and found that it was readily detectable in urine
pellet DNA (Additional file 1: Figure S2A). The quality
of the DNA was compatible with that seen from blood
and buccal smear DNA.
RNA integrity cellular pellet and exosomes
RNAs that reflect the population of epithelial cells lining
the urinary tract can be reproducibly recovered from a
Fig. 2 Immunoassay of soluble proteins. a Neutrophil gelatinase-associated lipocalin (NGAL) (b). Alpha-1 microglobulin (AMBP). c Retinol-binding
globulin. All 3 were stable at room temperature, 4 °C, and −20 °C in urine (shown in this figure) without preservatives and also with toluene, thymol,
and boric acid. None were stable with acetic acid, 6 N HCl, or 6 N HNO3 (Additional file 2: Table S3). Median and interquartile ranges are shown
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centrifuged urine pellet. Cellular pellet RNA quality was
not as consistent across samples collected from our clin-
ical laboratory, or in comparison to RNA from freshly
isolated chinese hamster ovary cells grown in cell culture
(used as control) (Additional file 1: Figure S2B, C, D).
We determined that a washing step should be included
to increase recovery of RNA (manuscript in preparation,
Wickman). However, RNA could still be recovered if the
pellet had been frozen at −80 °C in RNAlater® and the
washing step was subsequently performed on the thawed
sample, although recovery of RNA was reduced on
average by about 50 %. For low level transcripts (e.g.,
podocin), a urine volume of at least 30 mL will provide a
measurable signal in 80 % of normal urine samples. A
starting urine volume of less than 30 mL of urine in-
creases the undetectability rate. Urine mRNA amount
recovered decays by about 50 % over the first 4 h follow-
ing voiding, but then remains quite stable for up to 24 h
at 4 °C, compatible with the concept that a proportion
of voided cells remain intact within the urine milieu as a
potential source of RNA [23]. Abundant mRNAs, in-
cluding TGF-β1 and aquaporin 2, were detected in 95 %
of samples tested, whereas less abundant mRNA tran-
scripts for nephrin and podocin were detected in 88 %
Fig. 3 Western blot of exosome pellets. Exosomal proteins of interest including podocalyxin (PODXL), fibrocystin (FIBRO) and polycystin 1 (PC1)
were examined by Western blot after storage and compared with freshly-isolated exosomes. These proteins were best preserved by the Sigma
protease cocktail. a Polycystin 1 detection by Western blot was stable for 1 week at room temperature after exosomes were isolated and stored
in 0.01 % sodium azide (n = 7). However, polycystin 1 was not detected well from exosomes isolated after urine was frozen.at -80C probably
because of precipitation issues and unlikely due to loss of protease activity. Effects of preservatives on Western blot of exosome pellet proteins
PODXL, scramblase (PLSCR1), FIBRO, and smoothened (SMO). b Lane 1, Fresh, no preservatives; Lane 2, Fresh, no preservatives; Lane 3, −80 °C
Frozen/Thawed; Lane 4, −80 °C Frozen/Thawed. c Comparison of varied amounts of protease inhibitors on exosome protein detection by Western
blot. Initial assessment and following 6 months storage at −80 °C. Lane 1, 4.8 μL. Sigma protease inhibitor; Lane 2, 4.0 μL Sigma protease inhibitor;
Lane 3, 1:100 Roche Complete tablet; Lane 4, −80 °C Frozen/Thawed; Lane 5, Fresh, no preservatives. d Exosomal Podocalyxin fared well at RT
and at 4 °C. Sodium azide did not affect their survival. e Analysis of exosomes extracted from frozen (−80 °C) raw urine stored for 12 months
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of samples. Small RNA from cellular pellets was detected
(Additional file 1: Figure S2F,G). Out of 384 microRNAs
tested, 38 and 169 microRNAs were detected with a CT-
value less than 32 (robust detection) and 40 (borderline
detection), respectively, using a qRT-PCR array. Thus,
the urinary pellet is suitable for evaluation of RNA tran-
scripts and microRNAs, but is limited by transcript
abundance [23]. Alternatively, in exosome subfractions
which have been reported to be enriched in small RNAs
(including microRNAs), we detected robust and consist-
ent small RNA content (Additional file 1: Figure S2E) as
others have observed [33–38], and have begun their
characterization using next generation sequencing.
Discussion
The NEPTUNE study is a multi-center trial that includes
the goal to establish a biorepository for future research
studies, including biomarker discovery. We have devel-
oped and implemented a uniform urine collection and
storage protocol for all study sites. The goal of this
protocol is to obtain and store urine samples and spe-
cific subfractions suitable for biomarker research in a
well-defined and large disease cohort. Stability data for
several promising candidate urinary biomarker proteins
(NGAL, RBP, and AMBP) demonstrate they can be reli-
ably measured in urine without preservatives and at
storage temperatures as low as −80 °C [8, 39]. Other
markers or urinary subfractions (e.g., exosomes) appear
to require use of protease inhibitors for long-term
storage.
While we have not exhausted every possible storage
scenario or its effect on every potential urine protein
biomarker, we have incorporated current best practices
with some consideration given to cost. Based on this and
other published data, frozen urine specimens preserved
at −80 °C should be adequate to study many soluble
urine biomarkers, including albumin [40].
The current study also demonstrates how the protocol
could be applied to the study of biologically-rich
exosome-like vesicles which contain proteins of podo-
cyte origin and more than 5,000 proteins and abundant
miRNA [35, 41–44]. Currently, our collection protocol
stores a subgroup of urine subfractions with protease in-
hibitor that are immediately frozen. This process appears
suitable for soluble protein analysis, and it may permit
samples to be used for urine exosome analysis [45]. Stor-
ing unprocessed raw urine or urine which has been pre-
spun at 4000 g for 15 min at 4 °C is not optimal for exo-
some recovery, as demonstrated by the poor yield of
PC1 after freezing at −80 °C (Fig. 3). This may be be-
cause of the tendency for proteins and salts to precipi-
tate out of urine as it thaws. We hypothesize that this
precipitate could interfere with purification by trapping
exosomes in the initial low speed spin down. Conversely,
the current studies suggest that proteins are stable for
Western blot analysis in purified exosomes when stored
at −80 °C for up to twelve months. Indeed, our prelimin-
ary analysis of urine stored at RT for up to 7 days indi-
cates that even under these conditions, samples might
be suitable for Western analysis of urinary vesicles.
To date, use of nanomembrane concentrators have
yielded exosome proteins of “very low purity,” is labori-
ous (~130 min), and not uniform, although it does avoid
the need for ultracentrifugation, which is impractical in
a clinical setting [22, 35, 46, 47]. Studies report use of
these concentrators on frozen raw urine to examine a
few selected exosome markers, but to date, all more ex-
tensive exosome proteomic studies have employed ultra-
centrifugation protocols and fresh urine [22, 42, 44, 45,
48, 49]. When a combination of nanomembrane concen-
trators and size exclusion chromatography was applied
to nephrotic patient urine samples, highly abundant sol-
uble proteins (e.g., albumin) obstructed the nanomem-
brane filter and led to identification of only a limited
proteome [50]. Our study and others suggests that pro-
tease inhibitors will be required to study certain exoso-
mal proteins [22, 44, 46, 49]. The Sigma protease
inhibitor appears superior to the Roche Complete tablet,
and in this study was significantly less expensive. Indeed,
an even lower concentration of the Sigma protease in-
hibitor may be just as effective as the concentration used
in our current storage protocol. Sigma protease inhibitor
was also easier to use since it is a liquid and can be used
on urine volumes <50 mL. A possible explanation for
the lower effectiveness could include the required extra
time to dissolve the tablet into solution.
There are a number of limitations to the scope of the
NEPTUNE Urine collection protocol. For one, the con-
sortium receives many requests for samples to examine
the validity of exploratory urine biomarkers. Each ana-
lyte will likely require stability studies, etc., to determine
optimal detection in urine, which will likely eventually
exhaust our stored urine aliquots. The number of sam-
ples that could be stored at each time point for each pa-
tient had to be weighed against what was practical and
financially feasible at the time the collection protocol
was developed. Our solution at the time was to also
store multiple aliquots from the 24-h urine collection,
and these samples are also accessible to requestors.
Apart from NEPTUNE, many additional cohort studies
and randomized trials are ongoing that employ protocols
for urine collection and storage. To our knowledge, urine
specimens collected and stored in these other protocols
vary and may not provide the same utility for biomarker
research as the NEPTUNE protocol. Many storage
methods are sufficient for studying traditional biomarkers
such as creatinine and albumin; however, it is unknown
the degree to which findings generated from urine
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samples processed with other protocols will provide com-
parable results in proteomic, metabolomic, RNA, and
miRNA discovery and validation studies on banked urine
Conclusions
Currently, there is an absence of large-scale biomarker dis-
covery and validation studies on urine collected from well-
defined glomerular disease cohorts [1, 44]. Biomarkers are
urgently needed to understand glomerular disease patho-
genesis and to assess responsiveness versus non-
responsiveness and possibly limit the duration of toxic ther-
apies. We report here our progress in establishing a stan-
dardized, practical, and cost-effective urine procurement
protocol that will facilitate research protocols on urine in
the NEPTUNE cohort, permit identification of markers of
diagnosis, prognosis, and responsiveness to therapy, or
markers indicative of the disease. We have provided add-
itional information on RNA and protein quality in urine
subfractions. We add to current knowledge on preservation
conditions in urine subfractions as they will be applied
across large multicenter clinical studies. Requests are now
being reviewed for use of NEPTUNE urine samples. We in-
vite the nephrology community to submit requests for the
use of these samples through the NEPTUNE Ancillary
Studies process (NEPTUNE-study.org).
Additional files
Additional file 1: Table S1. Standard Components of Two Commercially-
Available Protease Inhibitors and Cost Analysis. Tables S2. Urine based
primary outcome measures for the FSGS/MCD and MN Cohort NEPTUNE
Study. Figure S1. Western blot of podocyte proteins in urinary cell pellets
from pooled urine. Figure S2. (A) The MLPA and long-range PCR analysis of
PKD1 DNA in urinary cell pellets. Long-range PCR of exons 13-15 (~5kb) and
the nested PCR from a 1:1000 dilution of the long-range product. Nested
PCR product for PKD1 Exon 15 part 5. ( ~700kb). The DNA ladder is seen in
the second photograph. The loading order was Blood, Saliva, Urine, for
patient R2140. Comparison analysis of RNA. Quality RNA was obtained from
(B) control (RNA isolated from CHO cell line), (C & D) urine cellular pellets, (E)
exosomes. RNA integrity numbers are shown from representative samples.
(F) Impact on urine volume on reproducibility of mRNA yield for podocin,
nephrin, aquaporin2, TGF β1 transcripts and (G) Number of samples
(percent) with undetectable transcripts (patients vs. controls). Additional
Methods.
Additional file 2: Specimen Stability Worksheet.
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